Stained histopathology specimen showing purple-stained cells with red nuclei under light microscope.

Science & Systems6 h ago

Daraxonrasib shrinks pancreatic tumours, with some becoming undetectable

In a trial of 61 patients, daraxonrasib stopped or shrunk tumours in almost all.

Reported by The Guardian

Why it matters

Pancreatic cancer currently kills half of patients within three months; this could extend life for people facing one of the deadliest cancers.

In Australia. If approved for use, daraxonrasib could offer hope to Australian patients with advanced pancreatic cancer, which has very poor survival rates.

Key facts

61 patients
Trial size
90%
Tumours stopped growing
76.6%
One-year survival on daraxonrasib
40-45%
One-year survival on chemotherapy alone
The full story is in InSnipHow it unfolded, who said what, and the Deep Dive. Ten stories like this every day, each with its source.Open InSnipFree on iPhone and Android, no account neededThe Deep Dive in the InSnip app

Next in today's edition

  1. Sport & PlayJamal Fogarty set for Wests Tigers move from Manly Sea EaglesThe Age, 3 h ago
  2. Technology & ToolsUS law enforcement database hacked, raising new cyber alarmPerthNow, 3 h ago
  3. Money & WorkAnthropic raises record $81 billion in historic stock market listingThe Conversation, 9 h ago

That is one of today's ten. Read the other nine, or send all ten.

Start tomorrow knowing what matters

  • Ten stories at 7am, nothing else
  • Every one with its source named
  • About seven minutes to read, free, one tap to stop

One email a day. We never share your address.

Inside InSnip

The news in ten short stories a day, each with its source, and the tools for life in Australia.

Victoria votes, Saturday 28 NovemberCoalition 57, Labor 43 after preferences in the latest poll. Make your call and find your seat.

Open InSnipFree on iPhone and Android, no account needed